Research Papers:

Exosomal miRNAs species in the blood of small cell and non-small cell lung cancer patients

Valeriy Poroyko, Tamara Mirzapoiazova, Arin Nam, Isa Mambetsariev, Bolot Mambetsariev, Xiwei Wu, Aliya Husain, Everett E. Vokes, Deric L. Wheeler and Ravi Salgia _

PDF  |  HTML  |  How to cite

Oncotarget. 2018; 9:19793-19806. https://doi.org/10.18632/oncotarget.24857

Metrics: PDF 2205 views  |   HTML 4700 views  |   ?  


Valeriy Poroyko1, Tamara Mirzapoiazova1, Arin Nam1, Isa Mambetsariev1, Bolot Mambetsariev1, Xiwei Wu2, Aliya Husain3, Everett E. Vokes3, Deric L. Wheeler4 and Ravi Salgia1

1Department of Medical Oncology and Therapeutics Research, City of Hope National Medical Center, Duarte, CA, USA

2Department of Molecular and Cellular Biology, City of Hope National Medical Center, Duarte, CA, USA

3Department of Medicine, University of Chicago, Chicago, IL, USA

4Department of Pathology and Laboratory Medicine, University of Wisconsin-Madison, Madison, WI, USA

Correspondence to:

Ravi Salgia, email: [email protected]

Keywords: exosome; miRNA; NSCLC; SCLC; liquid biopsy

Received: January 12, 2018     Accepted: March 02, 2018     Published: April 13, 2018


Lung cancer is a devastating disease with overall bleak prognosis. Current methods to diagnose lung cancer are rather invasive and are inadequate to detect the disease at an early stage when treatment is likely to be most effective. In this study, a shotgun sequencing approach was used to study the microRNA (miRNA) cargo of serum-derived exosomes of small cell lung cancer (SCLC) (n=9) and non-small cell lung cancer (NSCLC) (n=11) patients, and healthy controls (n=10). The study has identified 17 miRNA species that are differentially expressed in cancer patients and control subjects. Furthermore, within the patient groups, a set of miRNAs were differentially expressed in exosomal samples obtained before and after chemotherapy treatment. This manuscript demonstrates the potential of exosomal miRNAs for developing noninvasive tests for disease differentiation and treatment monitoring in lung cancer patients.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 24857